Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the persistence of benefit of LibiGel
(testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of
Hypoactive Sexual Desire Disorder (HSDD) in surgically menopausal women.